Hagenaars N - Search Results

1

Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.

Hagenaars N, Mania M, de Jong P, Que I, Nieuwland R, Slütter B, Glansbeek H, Heldens J, van den Bosch H, Löwik C, Kaijzel E, Mastrobattista E, Jiskoot W. Hagenaars N, et al. J Control Release. 2010 May 21;144(1):17-24. doi: 10.1016/j.jconrel.2010.01.027. Epub 2010 Jan 25. J Control Release. 2010. PMID: 20100528

2

Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.

Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W. Hagenaars N, et al. Vaccine. 2008 Dec 2;26(51):6555-63. doi: 10.1016/j.vaccine.2008.09.057. Vaccine. 2008. PMID: 18848856

3

Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Hagenaars N, Mastrobattista E, Verheul RJ, Mooren I, Glansbeek HL, Heldens JG, van den Bosch H, Jiskoot W. Hagenaars N, et al. Pharm Res. 2009 Jun;26(6):1353-64. doi: 10.1007/s11095-009-9845-y. Epub 2009 Feb 18. Pharm Res. 2009. PMID: 19224344

4

Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.

Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W. Hagenaars N, et al. J Control Release. 2009 Dec 3;140(2):126-33. doi: 10.1016/j.jconrel.2009.08.018. Epub 2009 Aug 25. J Control Release. 2009. PMID: 19712713

5

A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine.

Verheul RJ, Hagenaars N, van Es T, van Gaal EV, de Jong PH, Bruijns S, Mastrobattista E, Slütter B, Que I, Heldens JG, van den Bosch H, Glansbeek HL, Hennink WE, Jiskoot W. Verheul RJ, et al. Among authors: hagenaars n. Eur J Pharm Sci. 2012 Mar 12;45(4):467-74. doi: 10.1016/j.ejps.2011.10.001. Epub 2011 Oct 8. Eur J Pharm Sci. 2012. PMID: 22009112

6

Rational design of nasal vaccines.

Slütter B, Hagenaars N, Jiskoot W. Slütter B, et al. Among authors: hagenaars n. J Drug Target. 2008 Jan;16(1):1-17. doi: 10.1080/10611860701637966. J Drug Target. 2008. PMID: 18172815 Review.

7

Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.

Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W. Slütter B, et al. Among authors: hagenaars n. Vaccine. 2010 Aug 31;28(38):6282-91. doi: 10.1016/j.vaccine.2010.06.121. Epub 2010 Jul 16. Vaccine. 2010. PMID: 20638455

8

Improving the evaluation of worldwide biomedical research output: classification method and standardised bibliometric indicators by disease.

van de Laar L, de Kruif T, Waltman L, Meijer I, Gupta A, Hagenaars N. van de Laar L, et al. Among authors: hagenaars n. BMJ Open. 2018 Jun 4;8(6):e020818. doi: 10.1136/bmjopen-2017-020818. BMJ Open. 2018. PMID: 29866730 Free PMC article.

9

[Quantifying the biomedical research agenda of the Netherlands].

de Kruif TM, van de Laar LA, Hagenaars N. de Kruif TM, et al. Among authors: hagenaars n. Ned Tijdschr Geneeskd. 2017;161:D1333. Ned Tijdschr Geneeskd. 2017. PMID: 28659206 Review. Dutch.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters